Intellia Therapeutics Inc

Intellia Therapeutics to reveal Phase III data for CRISPR gene‑editing therapy lonvoguran ziclumeran, a potential curative treatment for hereditary angioedema.

Intellia Therapeutics

Intellia Therapeutics (NTLA) gene‑editing stock dips to $13.95, hovering mid‑52‑week range. Learn why investors, led by ARK, see long‑term promise amid current volatility.

Intellia Therapeutics has completed enrollment in its Phase-3 clinical trial for Lonvoguran Ziclumeran, a gene-editing therapy for hereditary angioedema, a significant milestone in the company’s pursuit of regulatory approval.

Intellia Therapeutics, Inc. is a leader in gene editing therapies, navigating market fluctuations while investing in research and development to potentially revolutionize treatment paradigms for genetic disorders.

Intellia Therapeutics, Inc. is a pioneering biotech company that is making significant strides in gene editing therapies, despite market fluctuations, and is poised to shape the future of healthcare.

Intellia Therapeutics is a pioneering biotech company specializing in gene editing therapies, with a promising pipeline of treatments for genetically-based diseases despite facing financial challenges.

Intellia Therapeutics Inc. reports strong Q1 2025 financial performance, exceeding analyst expectations, and announces key milestones in its gene editing therapies, including progress in Phase 3 clinical trials for HAE treatment.

Intellia Therapeutics continues to make strategic moves to bolster its position in the gene editing space, despite facing market volatility and challenges, with a focus on attracting top talent and advancing its pipeline of CRISPR-based therapies.